Psilocybin Therapy in Canada

Psilocybin therapy (also called psilocybin assisted therapy, psilocybe therapy, or mushroom therapy) is a form of psychedelic therapy currently undergoing clinical trials. It combines a powerful psychedelic experience under the influence of psilocybin with traditional talk therapy. It is being studied as a potential way to support cognitive, emotional, and psychological well-being in patients with various mental health conditions.

Researches hypothesize that the psychedelic experience—sometimes referred to as the “journey”—may allow a client to access memories, emotions, and insights that would not otherwise be available in a normal state of consciousness. It's an evolving approach, and ongoing trials are providing new insights into its safety and efficacy.

Here’s everything you need to know about psilocybin therapy in Canada.

What does psilocybin therapy look like in clinical trials?

In research settings, a course of psilocybin assisted therapy generally follows four steps:

• Step 1: Screening and education. Researchers assess whether a participant is eligible for the trial, review their medical and psychiatric history, and explain the potential benefits and risks of taking part.

• Step 2: Preparation. The participant attends one or more sessions with the study's therapists to prepare for the dosing session, set expectations, and build trust with the team who will be present.

• Step 3: The dosing session. The participant receives psilocybin in a controlled setting, typically with two trained facilitators present for the entire session, which can last several hours.

• Step 4: Integration. In follow-up sessions, the participant works with a therapist to process and contextualize the experience. Researchers consider integration central and integral to the approach, since the psychedelic experience can be confusing or distressing on its own.

Protocols vary between studies, and researchers are still working out which elements of the approach matter most.

Psilocybe therapy is not a one-size-fits all solution. And it’s just one aspect of a larger modality called psychedelic therapy. For a broader look at where psychedelic therapy research stands in Canada, see Psychedelics for Therapy 101: What Canadians Need to Know.

Is psilocybin mushrooms therapy the same thing as psilocybin therapy?

The terms are often used interchangeably, and they refer to the same underlying compound. The distinction that matters is between whole mushrooms and pharmaceutical psilocybin.

Clinical trials use synthetic, pharmaceutical-grade psilocybin in precisely measured doses. This allows researchers to know exactly what participants are receiving and to study its effects consistently.

Psilocybin-containing mushrooms, by contrast, vary widely in potency between species, batches, and even individual mushrooms. They also contain related compounds such as psilocin and baeocystin whose effects are less studied. Mushrooms sold illegally in Canada are unregulated, untested, and carry the added risks of unknown dosage and misidentified species.

How does psilocybin therapy work?

In clinical trials, the integration stage is where participants work to draw insights from the experience, and researchers believe this stage is central to any therapeutic effect.

Researchers are still working out the mechanisms. Psilocybin's active form, psilocin, acts primarily on serotonin receptors in the brain, and imaging studies suggest it temporarily changes activity in networks associated with self-referential thinking. One hypothesis is that this creates a window of psychological flexibility that talk therapy can build on, which is why trial protocols pair the dosing session with preparation and integration work.

The clinical evidence is early. Systematic reviews and meta-analyses of psilocybin trials report reductions in symptoms among participants, while noting the same limitations: small sample sizes, difficulty blinding participants to whether they received the drug, and short follow-up periods. Narrative reviews reach similar conclusions. Larger trials are underway, and no regulator has yet judged the evidence sufficient to approve psilocybin as a treatment.

What are the effects of psilocybin therapy?

The experience varies widely from one person to the next, depending on dosage, setting, and individual psychology. Psychedelic experiences are highly subjective: one trial participant may describe a profound mental or spiritual epiphany, while another, at the same dose, may find the experience frightening or destabilizing. Distressing experiences are common enough that trial protocols keep trained facilitators present for the entire dosing session.

In either case, researchers consider integration essential. In follow-up sessions, participants work with therapists to make sense of what happened, whether the experience was positive or difficult.

Psilocybin and antidepressants

Few studies have examined the risks of combining psilocybin with antidepressants. In clinical trials, participants taking SSRIs are typically tapered off under medical supervision before receiving psilocybin, partly because some antidepressants appear to blunt psilocybin's effects and partly because the interactions are not well understood.

Before you stop taking any drugs you’ve been prescribed to treat depression, whether by stopping all at once, or by tapering off your dosage, talk to your prescribing doctor. 

Quitting antidepressants may cause antidepressant discontinuation syndrome, which has wide ranging negative effects. It might also lead to an increase in depressive symptoms, including suicidal ideation.

Magic mushroom dispensaries in Canada

Magic mushrooms and psilocybin are illegal in Canada, and that includes the dispensaries that openly sell them in many cities. These storefronts operate outside the law, and several have been raided by law enforcement. Possession of psilocybin mushrooms in any quantity remains a criminal offence, and anyone buying from a dispensary can be charged. Dispensary products are also completely unregulated: there is no oversight of what species, potency, or contaminants are in what's sold.

Key takeaways:

• Psilocybin is a controlled substance in Canada, and no psilocybin product has been authorized for sale by Health Canada. Its safety and effectiveness are still under investigation

• Clinical trials pair pharmaceutical-grade psilocybin with structured preparation and integration therapy, and researchers consider the evidence promising and incomplete

• Psilocybin carries real risks, including frightening or destabilizing experiences, poorly understood interactions with antidepressants, and, outside of trials, unregulated products and criminal liability

• Anyone seeking support for depression or other mental health challenges can work with a licensed therapist using established, legal approaches